Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects age 18 and over and of either gender.~2. Scheduled to receive CT scan with intravenous contrast dye.~3. Non diabetics or subjects with type 1 or 2 diabetes mellitus~4. Written informed consent.~5. Subjects who are on diuretics and non-steroidal inflammatory agents will not be excluded.~6. Subjects who have received n-acetylcysteine or sodium bicarbonate pre CT scan will not be excluded~Exclusion Criteria:~1. Pregnant or lactating women.~2. End-stage renal disease (on hemodialysis or peritoneal dialysis)~3. A known history of acute renal failure~4. Subjects receiving glucophage/metformin or glucovance~5. Subjects who cannot give written informed consent.~6. Subjects receiving peritoneal dialysis or hemodialysis.~7. Subjects enrolled in another investigational drug study ≤ 30 days of enrollment into the present study.~8. Subjects with a known hypersensitivity or anaphylaxis to contrast dye or iodine.~9. Subjects with known hypersensitivity or anaphylaxis to erythropoietin, mammalian-cell derived products, or human albumin.~10. Age \< 18 years~11. Use of any erythropoietin replacement or transfusion within the prior 3 days~12. Baseline Hemoglobin \> 12.0 g/dL~13. Uncontrolled hypertension, systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg in any recording in the past 24 hours.~14. Evidence of hemodynamic instability~15. Subject unable to follow protocol due to mental incompetence or other reason~16. Inaccessibility of medical record~17. Subjects with a history of MI, CVA, active angina or unstable angina within the past three months~18. Subjects with a history of current malignancy, where current malignancy is defined as subjects undergoing treatment with chemotherapy or radiation therapy, subjects with known metastatic disease, and those with terminal malignant disease.~19. Subject with any known history of seizure disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erythropoeitin (Type: PLACEBO_COMPARATOR): Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).